IMO
Nothing wrong here - normal biotech business
CR's are always a constant with biotechs - hitting the market constantly for cash is nothing new in this game
The 30 patient data does not imo seem strong enough to merit a CR at well above market
Capital raises between inflection points only benefits a select few
Newbies note - we were told that no cash required until 1st Half 2021 - unreal and misleading statements. imo
DYOR
- Forums
- ASX - By Stock
- KZA
- Question for James Garner/CC
Question for James Garner/CC, page-2
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)